According to new research, about two of the three who aimed to lose weight in search of weight loss, have stopped using ozempic and victoza drugs within a year.
About 65 % of people without diabetes stopped drugs within a year. Type 2 diabetic patients were more likely to stay in drug therapy for at least one year. Also, people with high income and few side effects were more likely to stay on expensive drugs. study It was released on JAMA Network Open on Friday.
According to researchers of TRUVETA, a medical research company based in Belview, Washington, the higher smoking cessation rate among non -diabetic patients is probably due to cost.
The health insurance company covers a wide range of diabetes drugs of this class Gurkagon Peptide 1 (GLP-1), but insurance companies do not often pay for these drugs. Researchers said that the list price exceeded $ 1,000 per month, which means that many consumers can afford to buy medicine.
This study based on a computerized medical record review revealed that patients with high income are unlikely to quit medicine.
Do you need a break? Play US toDay Daily Crossword Puzzle.
“We were impressed that we were impressed by the high cancellation rate,” said Truveta's researcher and researcher, TRICIA RODRIGUEZ. “Type 2 diabetes requires insurance and cost issues to make it difficult to access these drugs.”
People with few side effects, better results, stick to these drugs for a long time
In this study, we analyzed more than 125,000 adult records from January 2018 to December 2023, which started taking GLP-1 drug lagurtide, semagultide, or tilzepachid. These drugs are prescribed for weight loss or diabetes under different brand names.
NOVO Nordisk sells drug Sempgridide on WEGOVY for Ozempic brands and weight loss for diabetes. Liraglutide, the company's old -weight loss, is sold as a security VICTOZA for weight loss. Eri Lilly's Tilzepachido did not collide with the market as a diabetes Moon Jaro until 2022, so Zeppund was taking this medicine until 2023.
In this study, the removal rate was calculated regardless of the presence or absence of diabetes.
The side effects of excavation also urged to quit the medicine. Those who had medium or severe digestive side effects were more likely to stop the medicine. In the case of severe, the patient sue for drug manufacturers and appeals for drug therapy.
This study shows that the results of the patient are important. Those who cut more pounds are more likely to stick to the medicine. And those who regain their weight after stopping the drug are more likely to give the drug a second attempt.
Patients often have a hard time getting medicine
Many employers have a limited range of obesity health insurance. In some states such as North Carolina, the compensation of obese drugs has been deleted for employees and their families. Last year, only 1 % of the affordable care method market planned covered these drugs for obesity, According to the June analysis KFF, a non -profit health policy organization.
Medicare is an adult federal health program for adults over 65 and restricts compensation for people with diabetes or heart disease.
In November last year, the Biden administration announced plans to expand obesity compensation to more than 7 million medical care and registrants of Medicade since 2026. However, the Trump administration needs to determine the rules and know how to pay a price tag of about $ 40 billion. The US Ministry of Health officials have not commented on this proposal.
Ezekiel Emmanuel, a co -director of the University of Pennsylvania's Healthcare Transformation Institute, said that the possibility of these weight loss drugs could only be achieved when people could afford to buy medicine and can be accessed.
“This study shows the task of maintaining these drugs, and needs to work on barriers such as costs to ensure use, compensation for insurance, and fair policies. I am emphasized. “” If there are no measures, there is a risk of countless denying the opportunity to improve the quality of health and life. “
